0001593968-20-002179.txt : 20201110
0001593968-20-002179.hdr.sgml : 20201110
20201110183303
ACCESSION NUMBER: 0001593968-20-002179
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201106
FILED AS OF DATE: 20201110
DATE AS OF CHANGE: 20201110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ignelzi Troy A.
CENTRAL INDEX KEY: 0001579829
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38958
FILM NUMBER: 201302457
MAIL ADDRESS:
STREET 1: C/O ESPERION THERAPEUTICS, INC.
STREET 2: 46701 COMMERCE CENTER DRIVE
CITY: PLYMOUTH
STATE: MI
ZIP: 48170
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karuna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001771917
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270605902
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 33 ARCH STREET
STREET 2: SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 857-449-2244
MAIL ADDRESS:
STREET 1: 33 ARCH STREET
STREET 2: SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
primary_01.xml
PRIMARY DOCUMENT
X0306
4
2020-11-06
0001771917
Karuna Therapeutics, Inc.
KRTX
0001579829
Ignelzi Troy A.
C/O KARUNA THERAPEUTICS, INC.
33 ARCH ST STE 3110
BOSTON
MA
02110-1424
false
true
false
false
Chief Financial Officer
Common Stock
2020-11-06
4
M
false
564
9.2
A
5564
D
Common Stock
2020-11-06
4
S
false
564
108.15
D
5000
D
Common Stock
2020-11-09
4
M
false
8000
9.2
A
13000
D
Common Stock
2020-11-09
4
S
false
8000
105.02
D
5000
D
Common Stock
2020-11-09
4
M
false
1318
9.2
A
6318
D
Common Stock
2020-11-09
4
S
false
1318
108.26
D
5000
D
Common Stock
2020-11-10
4
M
false
118
9.2
A
5118
D
Common Stock
2020-11-10
4
S
false
118
103.48
D
5000
D
Option (right to buy)
9.20
2020-11-06
4
M
false
564
0
D
2020-03-01
2029-03-21
Common Stock
564
235230
D
Option (right to buy)
9.20
2020-11-09
4
M
false
8000
0
D
2020-03-01
2029-03-21
Common Stock
8000
227230
D
Option (right to buy)
9.20
2020-11-09
4
M
false
1318
0
D
2020-03-01
2029-03-21
Common Stock
1318
225912
D
Option (right to buy)
9.20
2020-11-10
4
M
false
118
0
D
2020-03-01
2029-03-21
Common Stock
118
225794
D
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.05 to $109.08, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
/s/ Troy Ignelzi
2020-11-10